Conversely, when ARID1A expression was restored in HEC-1A (endometrial cancer cell) using a doxycycline ARID1A-inducible (ARID1AInduce) system, the cells were significantly less sensitive to both BRD4i-ATRi and BRD4i-WEE1i treatment as assessed by cell viability (Both P < 0.01, + doxycycline vs. - doxycycline) and colony formation ability (Both P < 0.001 + doxycycline vs. - doxycycline Fig. 2E–F, Supplementary Fig. 2C). Here, ARID1A is linked to endometrial cancer.